IceCure Medical nine-month 2026 net loss widens 20% to $13 million
ICCM•IceCure Medical’s net loss widened 20% year over year to $13 million for the nine months ended September 30, 2026, while revenue rose 26% to $2.64 million. Operating cash outflow increased 32% to $12.58 million, and cash and cash equivalents totaled $8.22 million.
1. Nine-month results
IceCure Medical reported a net loss of $13 million for the nine months ended September 30, 2026, up 20% year over year. Revenue rose 26% to $2.64 million, while operating cash outflow increased 32% to $12.58 million; cash and cash equivalents totaled $8.22 million at September 30.
2. Commercial and study updates
The company’s U.S. commercial reach expanded to 21 states in the third quarter, compared with 11 states a year earlier. After quarter-end, the ChoICE breast cancer study enrolled its first two patients and completed its first ProSense cryoablation treatment.




